T1	Participants 52 71	uremic pericarditis
T2	Participants 207 271	24 patients with endstage chronic renal failure and pericarditis
T3	Participants 304 368	25 mg four times daily, (11 patients) or a placebo (13 patients)
#1	AnnotatorNotes T3	11+13 patients involved in the study
